GlassScriptPhysician profile
Austin Longberg
NPI 1336503416
$12,304.75
in general payments reported to CMS, 2019-2025
35 companies · $2,688 in 2025
The $2,688 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $408 · 2021: $933 · 2022: $1,386 · 2023: $2,254 · 2024: $3,535 · 2025: $2,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,040 · Education: $425 · Travel and Lodging: $12.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,040.29 |
| Education | $424.50 |
| Travel and Lodging | $12.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,390.68 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,344.10 | 2019-2025 | |
| Pfizer INC. | $1,342.63 | 2019-2025 | |
| Abbvie INC. | $993.55 | 2019-2025 | |
| Janssen Biotech, INC. | $856.77 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $783.92 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $703.11 | 2020-2025 | |
| Leo Pharma INC. | $669.44 | 2021-2025 | Adbry |
| Mayne Pharma Commercial LLC | $584.16 | 2023-2025 | |
| Incyte Corporation | $582.40 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $517.70 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $311.12 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $288.98 | 2021-2025 | |
| Ucb, INC. | $274.65 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $238.04 | 2023-2025 | Sotyktu |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $229.50 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $223.03 | 2022-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $175.33 | 2020-2024 | Arazlo, Jublia, Duobrii |
| Celgene Corporation | $116.79 | 2019 | |
| Epi Health, LLC | $99.98 | 2021-2022 | |
| Journey Medical Corporation | $86.15 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.02 | 2022-2024 | Spevigo |
| Sun Pharmaceutical Industries INC. | $64.97 | 2022-2025 | |
| Organon LLC | $51.38 | 2025 | Vtama |
| Botanix Sb INC | $43.54 | 2025 | Sofdra |
| Glaxosmithkline, LLC. | $41.39 | 2024-2025 | Shingrix, Arexvy |
| Almirall LLC | $41.23 | 2023-2025 | Seysara, Klisyri |
| Kowa Pharmaceuticals America, INC. | $37.50 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $28.89 | 2024 | Ycanth |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Shield Therapeutics INC | $21.84 | 2022 | |
| Ani Pharmaceuticals, INC. | $18.47 | 2025 | Purified Cortrophin Gel |
| Strata Skin Sciences, INC. | $17.42 | 2025 | Xtrac |
| Novo Nordisk INC | $17.22 | 2025 | |
| Biofrontera INC. | $10.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Longberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.